These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 2025730)
1. Cholesterol screening and life assurance. Neil HA; Mant D BMJ; 1991 Apr; 302(6781):891-3. PubMed ID: 2025730 [TBL] [Abstract][Full Text] [Related]
2. Low serum total cholesterol concentrations and mortality in middle aged British men. Wannamethee G; Shaper AG; Whincup PH; Walker M BMJ; 1995 Aug; 311(7002):409-13. PubMed ID: 7640584 [TBL] [Abstract][Full Text] [Related]
3. Long-term outcome in 53 patients with homozygous familial hypercholesterolaemia in a single centre in France. Bruckert E; Kalmykova O; Bittar R; Carreau V; Béliard S; Saheb S; Rosenbaum D; Bonnefont-Rousselot D; Thomas D; Emery C; Khoshnood B; Carrié A Atherosclerosis; 2017 Feb; 257():130-137. PubMed ID: 28131047 [TBL] [Abstract][Full Text] [Related]
4. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ; 1991 Oct; 303(6807):893-6. PubMed ID: 1933004 [TBL] [Abstract][Full Text] [Related]
5. Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia. Bhatnagar D; Morgan J; Siddiq S; Mackness MI; Miller JP; Durrington PN BMJ; 2000 Dec; 321(7275):1497-500. PubMed ID: 11118175 [TBL] [Abstract][Full Text] [Related]
6. Dutch Lipid Clinic Network low-density lipoprotein cholesterol criteria are associated with long-term mortality in the general population. Séguro F; Bongard V; Bérard E; Taraszkiewicz D; Ruidavets JB; Ferrières J Arch Cardiovasc Dis; 2015 Oct; 108(10):511-8. PubMed ID: 26073227 [TBL] [Abstract][Full Text] [Related]
7. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study. Kastelein JJ; Besseling J; Shah S; Bergeron J; Langslet G; Hovingh GK; Al-Saady N; Koeijvoets M; Hunter J; Johnson-Levonas AO; Fable J; Sapre A; Mitchel Y Lancet; 2015 May; 385(9983):2153-61. PubMed ID: 25743173 [TBL] [Abstract][Full Text] [Related]
8. Molecular screening for familial hypercholesterolaemia: consequences for life and disability insurance. Homsma SJ; Huijgen R; Middeldorp S; Sijbrands EJ; Kastelein JJ Eur J Hum Genet; 2008 Jan; 16(1):14-7. PubMed ID: 17957228 [TBL] [Abstract][Full Text] [Related]
9. Lipid screening: is it enough to measure total cholesterol concentration? Neil HA; Mant D; Jones L; Morgan B; Mann JI BMJ; 1990 Sep; 301(6752):584-7. PubMed ID: 2082960 [TBL] [Abstract][Full Text] [Related]
10. Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. Benn M; Watts GF; Tybjærg-Hansen A; Nordestgaard BG Eur Heart J; 2016 May; 37(17):1384-94. PubMed ID: 26908947 [TBL] [Abstract][Full Text] [Related]
11. Familial hypercholesterolaemia: pilot study to identify children at risk. Taylor CJ; Olpin S; Rattenbury J; Whippey A; Lunt C; Beckles-Willson N; Higginbottom J; Pollitt RJ; Bonham J; Taitz LS J Clin Pathol; 1993 Aug; 46(8):730-3. PubMed ID: 8408697 [TBL] [Abstract][Full Text] [Related]
12. High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study. Langsted A; Kamstrup PR; Benn M; Tybjærg-Hansen A; Nordestgaard BG Lancet Diabetes Endocrinol; 2016 Jul; 4(7):577-87. PubMed ID: 27185354 [TBL] [Abstract][Full Text] [Related]
13. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis. Leipold R; Raal F; Ishak J; Hovingh K; Phillips H Eur J Prev Cardiol; 2017 Nov; 24(17):1843-1850. PubMed ID: 28925748 [TBL] [Abstract][Full Text] [Related]
14. British family heart study: its design and method, and prevalence of cardiovascular risk factors. Family Heart Study Group Br J Gen Pract; 1994 Feb; 44(379):62-7. PubMed ID: 8179948 [TBL] [Abstract][Full Text] [Related]
16. Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis. Marks D; Wonderling D; Thorogood M; Lambert H; Humphries SE; Neil HA Health Technol Assess; 2000; 4(29):1-123. PubMed ID: 11109029 [TBL] [Abstract][Full Text] [Related]
17. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group. Atherosclerosis; 1999 Jan; 142(1):105-12. PubMed ID: 9920511 [TBL] [Abstract][Full Text] [Related]
18. The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men. Scartezini M; Hubbart C; Whittall RA; Cooper JA; Neil AH; Humphries SE Clin Sci (Lond); 2007 Dec; 113(11):435-41. PubMed ID: 17550346 [TBL] [Abstract][Full Text] [Related]
19. Cardiovascular risk factors and lipoprotein profile in French Canadians with premature CAD: impact of the National Cholesterol Education Program II. McNicoll S; Latour Y; Rondeau C; Bouthillier D; Davignon J; Genest J Can J Cardiol; 1995 Feb; 11(2):109-16. PubMed ID: 7866933 [TBL] [Abstract][Full Text] [Related]
20. Screening for hyperlipidaemia in childhood. Recommendations of the British Hyperlipidaemia Association. Wray R; Neil H; Rees J J R Coll Physicians Lond; 1996; 30(2):115-8. PubMed ID: 8709055 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]